Clinical predictors of efavirenz-based regimen treatment durability: A two-year case-control study of antiretroviral-naïve patients

Fahrni, Mathumalar Loganathan; Misran, Nurul Fatin Laila; Abidin, Zarena Zainul; Chidambaram, Suresh Kumar; Lazzarino, Antonio Ivan

doi:10.1016/j.jiph.2022.12.001

Cited by 3 publications

(4 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our results are consistent with previous studies showing that symptoms of sleep disorders, anxiety, and depression are common among PLWH. 16 , 17 , 25 Consistent with a previous study, our analysis revealed a dynamic correlation among sleep disorders, anxiety, and depression symptoms over the 12-month treatment period. 4 Our data also demonstrate a greater correlation between sleep disorders and anxiety symptoms than between sleep disorders and depression symptoms in PLWH, and this is consistent with a previous study among healthy individuals.…”

Section: Discussionsupporting

confidence: 90%

“…3 So far, EFV-associated NPAEs have been reported in Africa, [11][12][13] Europe, 14 and other locations. [15][16][17][18] The integrase strandtransfer inhibitors raltegravir, elvitegravir (EVG), dolutegravir (DTG), and bictegravir are approved by the US Food and Drug Administration for treatment-naive individuals initiating ART. 19 Adoption of DTG-based ART is increasing in European countries and economically developed areas, 20,21 and the risks of DTG-associated NPAEs including anxiety, depression and other symptoms have been studied.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Neuropsychiatric Adverse Events Following Antiretroviral Therapy in People Living with HIV: A Real-World Study of Dynamic Trends and Risk Factors in Hangzhou, China

Zhang¹,

Wang²,

Li³

et al. 2023

IDR

View full text Add to dashboard Cite

Purpose Neuropsychiatric adverse events (NPAEs) occur frequently in people living with human immunodeficiency virus (PLWH) receiving antiretroviral therapy (ART). This study aimed to assess the dynamic trends and risk factors of NPAEs among PLWH in Hangzhou taking efavirenz (EFV)- or dolutegravir (DTG)- or elvitegravir (EVG)-based regimens. Patients and Methods A total of 287 ART-naive PLWH were included in this study, EFV (400mg)- (n = 122), EFV (600mg)- (n = 37), DTG- (n = 73), EVG-based (n = 47) and other ART regimens (n = 8) as the initial ART regimen were administered for 12 months. All data were collected at five time points within a 12-month follow-up. The Pittsburgh Sleep Quality Index and Hospital Anxiety and Depression Scale were used to evaluate sleep disorders and anxiety and depression symptoms, respectively. The dynamic trends and potential risk factors of NPAEs were investigated using a generalized linear mixed model. Results Mean age was 29.4 (SD: 7.5) years with 97.2% males. After 12 months of ART, the prevalence of sleep disorders and anxiety decreased significantly, although only a slight improvement was observed for depression. In addition, there was a significant positive correlation between sleep disorders, anxiety, and depression. The risk factors for NPAEs differed slightly depending on the choice of ART regimen, but the seven factors most commonly associated with NPAEs were age, sex, marital status, education level, smoking status, body mass index, and WHO clinical stage. Treatment-induced changes in CD4-positive T-cell count and virological suppression did not depend on the particular choice of ART regimen. Conclusion The prevalence of sleep disorders and anxiety changed significantly over time on ART and the risks of these disorders were associated with seven common clinical and demographic factors.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Introductionmentioning

confidence: 99%

Neuropsychiatric Adverse Events Following Antiretroviral Therapy in People Living with HIV: A Real-World Study of Dynamic Trends and Risk Factors in Hangzhou, China

Zhang¹,

Wang²,

Li³

et al. 2023

IDR

View full text Add to dashboard Cite

show abstract

“…Продолжительность первой линии АРТ в течение 2 лет наблюдения составила 72%. 17 пациентов прекратили прием терапии по схеме EFV+2НИОТ по причине побочных эффектов, 8 пациентов -по причине неэффективности, 24 пациента -по другим причинам (ко-инфекция с вирусным гепатитом/туберкулезом, неудобство приёма, потеря из-под наблюдения) [5].…”

Section: результаты исследованияunclassified

“…Известно, что продолжительность жизни людей, живущих с ВИЧ, значительно увеличилась благодаря комплексу мер по оказанию специализированной медицинской помощи и имеющимся лекарственным препаратам [2]. Несмотря на это, в популяции пациентов нередки случаи изменения и прерывания курса терапии по ряду причин, в том числе по причине отсутствия вирусологического ответа, нежелательных явлений или несоблюдения режима терапии [3][4][5][6][7][8][9]. Изменение или отмена терапии могут повлечь за собой неблагоприятные клинические исходы заболевания и увеличение прямых и непрямых расходов системы здравоохранения.…”

unclassified

Durability of first-line antiretroviral treatment in the Russian Federation: retrospective study

Sizova,

Plotnikova,

Shimonova

et al. 2023

jour

View full text Add to dashboard Cite

Objective. To assess durability of antiretroviral therapy in first line in HIV-infected patients in real clinical practice in the Russian Federation and determine association between basic clinical and demographic characteristics and durability of treatment.Materials and methods. A non-interventional retrospective study was conducted collecting data from primary medical records of HIV-infected patients who signed informed consent form and had started antiretroviral therapy in first line. Patients were enrolled if the third component was a non-nucleoside reverse transcriptase inhibitor (NNRTI) or ritonavir boosted protease inhibitor (PI/r) plus two nucleoside reverse transcriptase inhibitors (NRTIs). Also, patients must have been followed up for at least 96 since start of treatment. Durability of therapy was retrospectively assessed at 48±8 and 96±8.Results. 536 patients were enrolled. Percentage of patients without change of therapy was approximately 76% and 60%, and the mean duration of therapy without changes was approximately 47 and 79 weeks at 48±8 and 96±8 weeks, correspondingly. Durability of treatment was not different for NNRTI+2NRTIs and PI/r+2NRTIs. Only age ≥ 40 years as a basic characteristic was associated with ART change prior to 96 weeks: OR=1.391, 95% CI 1.005-1.925.Conclusions. In real clinical practice in Russia, durability of first-line antiretroviral therapy corresponds published scientific data (in terms of percentage of patients without change of treatment and its duration without change). Durability of treatment and factors associated with its early switch or stop should be investigated in prospective studies further.

show abstract

Current advancements in therapy for Niemann-Pick disease: progress and pitfalls

Bremova-Ertl

Schneider

2023

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

Clinical predictors of efavirenz-based regimen treatment durability: A two-year case-control study of antiretroviral-naïve patients

Cited by 3 publications

References 25 publications

Neuropsychiatric Adverse Events Following Antiretroviral Therapy in People Living with HIV: A Real-World Study of Dynamic Trends and Risk Factors in Hangzhou, China

Neuropsychiatric Adverse Events Following Antiretroviral Therapy in People Living with HIV: A Real-World Study of Dynamic Trends and Risk Factors in Hangzhou, China

Durability of first-line antiretroviral treatment in the Russian Federation: retrospective study

Current advancements in therapy for Niemann-Pick disease: progress and pitfalls

Contact Info

Product

Resources

About